Skip to main content
Clinical Trials/NCT05234450
NCT05234450
Unknown
Not Applicable

Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and Carcinomas

University Hospital, Strasbourg, France1 site in 1 country300 target enrollmentDecember 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cancer of Pancreas
Sponsor
University Hospital, Strasbourg, France
Enrollment
300
Locations
1
Primary Endpoint
Establishment of the number of tumor subgroups by integrating data from all multi-omics analyses
Last Updated
4 years ago

Overview

Brief Summary

In this work, the investigators count through the integrated multi-omics analysis to identify different tumor subgroups in pancreatic neuroendocrine tumors and carcinomas regardless of their grade and stage. To achieve this, they will resort to the use of next-generation sequencing approaches (RNAseq, then use of MCP Counter for the absolute quantification of the eight populations of immune cells in the tumor microenvironment), alterations in epigenetics with study of the methylome by MeDIP, ChIPseq, telomere (ALT) study, as well as correlation with peripheral blood neutrophil to lymphocyte ratio and immunohistochemistry data such as Ki67, p53, Rb, DAXX, ATRX, PDL1, immune cell labeling. This will be done on frozen or paraffin material. This work will provide a more complete biological picture of pancreatic neuroendocrine tumors and carcinomas.

Registry
clinicaltrials.gov
Start Date
December 1, 2021
End Date
June 30, 2022
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital, Strasbourg, France
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Establishment of the number of tumor subgroups by integrating data from all multi-omics analyses

Time Frame: 1 month

Study Sites (1)

Loading locations...

Similar Trials